The findings demonstrate the effectiveness of CA19-9 CAR T cells in GI cancers using various pre-clinical tumor models, providing a rationale for further clinical development.
Abstract
Background
&
Aims
Chimeric antigen receptor (CAR) T cell therapy for pancreatic ductal adenocarcinoma (PDAC) has been challenging, in part due to the paucity of tumor-specific cell-surface targets. Here, we explored the design feasibility and anti-tumor efficacy of CAR T cells recognizing the CA19-9 glycan, a tumor antigen commonly associated with PDAC and other gastrointestinal tumors.
Methods
We designed and screened 14 CA19-9 CAR constructs harboring different single-chain variable fragments (scFvs) and intracellular signaling domains. After narrowing down to one optimal CAR configuration, we further evaluated its anti-tumor efficacy in various in vitro and in vivo models.
Results
Out of 14 CAR constructs tested, we identified one design - AbLIFT15.28z - that enabled robust T cell expansion and efficient tumor cell-killing properties. Experiments with human PDAC cell lines and patient-derived organoids (PDOs) revealed that AbLIFT15.28z CAR T cell-mediated cytotoxicity was confined to cancer cells expressing CA19-9, both in vitro and in vivo. We then tested the efficacy of AbLIFT15.28z CAR T cells in immunocompetent murine models of PDAC, revealing significant effects against both primary and metastatic tumors. Efficacy was not limited to PDAC, as robust and specific anti-tumor effects were observed against CA19-9-expressing tumors of the colon, stomach, esophagus, and biliary tract.
Conclusions
Our findings demonstrate the effectiveness of CA19-9 CAR T cells in GI cancers using various pre-clinical tumor models, providing a rationale for further clinical development.
Pancreatic ductal adenocarcinoma (PDAC) and lung adenocarcinoma (LUAD) remain lethal malignancies with limited therapeutic options, highlighting an urgent need for more effective treatments. Integrin αvβ6 (ITGB6) is a receptor preferentially expressed in specific types of tumors, such as PDAC and LUAD, and represents a...
Ling-Chao Shi, L. Qin, Shu-Xin Sun et al.· Molecular Cancer Therapeutic...· 0 citations
Pancreatic ductal adenocarcinoma (PDAC) remains refractory to immunotherapies, including adoptive T cell therapy, necessitating evaluation of alternative T cell engineering platforms in immunosuppressive solid tumors. Human CD4+ T cells co-secreting IFN-γ and IL-17A (Th1/17 hybrids) have demonstrated enhanced ant...
Delaney K. Geitgey, Megan M. Wyatt, Maggie J. Phillips et al.· Cancer Research· 0 citations
The combination of rational CAR design (CD28-ICOS signaling) and optimized delivery strategy provides a strong rationale for the clinical development of L1CAM-targeted CAR-T therapy, particularly in patients with L1CAM-positive solid tumors.
X. Che, Un-Jung Yun, Junsub Lee et al.· Journal for ImmunoTherapy of...· 0 citations
A humanized CD70-targeted CAR-T cell therapy is developed, A174-hu1-CAR-T, with reduced fratricide and potent antitumor activity, providing a preclinical foundation to support further translational development.
Meng-Jia Zhang, Zhi-Hao Wang, Cheng Gao et al.· International Immunopharmaco...· 1 citation
Chimeric antigen T cell therapy has entered into standard of care for hematologic malignancies such as B-ALL due to its robust efficacy. However, solid tumors such as pancreatic cancer pose challenges for CAR T cell therapies due to an immunosuppressive environment, antigen escape and tumor heterogeneity. As such...
This work provides a framework for identifying actionable treatment-induced peptide antigens and supports rational combination strategies pairing KRAS/RAS inhibitors with T cell-based immunotherapies, including BiTE, CAR-pMHC, TCR-T, and cancer vaccine approaches.
Wei-Xia Kang, Allison Glynn, Harshabad Singh et al.· Cancer Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.